BioCentury
ARTICLE | Financial News

Neurogene raises $68.5M series A for neurological disease gene therapies

February 12, 2019 12:05 PM UTC

Neurogene Inc. (New York, N.Y.) raised $68.5 million in a series A round to fund development of its adeno-associated viral (AAV)-based gene therapies to treat rare neurological diseases.

Samsara BioCapital, EcoR1 Capital, Cormorant Asset Management, Redmile Group and an undisclosed healthcare investment fund participated in the round...

BCIQ Company Profiles

Neurogene Inc.